For Portfolio Purposes Only. Developed independently as a sample of medical writing capabilities.

Psychiatry Pharmaceutical Advisory Board Executive Summary

Andre R. Alexander, MD, MSHIA

For Portfolio Purposes Only. Developed independently as a sample of medical writing capabilities.

Advisory Board: Monday, June 15, 2026, Princeton, NJ, N=15

Meeting Overview: The Advisory Board met with Key Opinion Leaders (KOLs) in Psychiatry to gather expert input regarding the clinical positioning of Centanafadine in Attention-Deficit/Hyperactivity Disorder (ADHD).

Key Themes/Consensus:

- KOLs agreed with the current prevailing treatment paradigm prioritizing stimulant medications as first-line treatment for ADHD.
- KOLs generally agreed that there exist enough options in the realm of extended-release methylphenidate and amphetamine compounds to avoid "crashes" in their patients, but some found difficulty in avoiding sleep disturbance.

Unmet Needs Identified:

- KOLs unanimously agreed that their patients complained about stimulant shortages at their local pharmacies.
- KOLs expressed concern regarding the abuse potential of the stimulant drugs, noting that it has become an increasing problem in their adolescent populations.
- One KOL brought up a complaint from an adult patient who requested an off-label dose increase for weight loss
- KOLs agreed that there is a great need for more efficacious, non-habit-forming treatments for ADHD
- KOLs had very little familiarity with our new product Centanafadine, the first-of-its kind norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI)
    - They were impressed the more they learned about it.

Proposed Action Items:

- Expand KOL education initiatives regarding Centanafadine, address any data gaps.
- Develop marketing strategy for Centanafadine emphasizing supply reliability and safety profile in pediatric populations.
- Assess the feasibility of expanding clinical development into weight-related indications, while critically evaluating the competitive threat posed by existing GLP-1 products in this space.
- Engage our government affairs colleagues on the regulatory hurdles limiting stimulant supply in the domestic market.
- Consider possible diversification of stimulant supply lines, to include foreign markets, advanced manufacturing technologies (e.g. Continuous Pharmaceutical Manufacturing)